Improving Patient Safety Through Access to Sugammadex in the PACU Setting
2024
- 4Usage
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Usage4
- Abstract Views4
Conference Paper Description
Prior to development of Sugammadex the frequency of residual neuromuscular paralysis in PACU has been documented to range from 4-50%. Residual paralysis is associated with many postoperative complications including hypoxia and respiratory failure. Following an incidence of inadequate muscular paralysis reversal leading to respiratory decompensation in PACU, we instituted a change in the way providers have access to Sugammadex within this setting. Sugammadex vials are now stocked within PACU Omnicell for urgent access and within the crash cart for emergent need. Providers have given positive feedback regarding this institutional change
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know